2. Academic Validation
  3. Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors

  • Invest New Drugs. 2011 Feb;29(1):137-43. doi: 10.1007/s10637-009-9347-0.
Neeltje Steeghs 1,  Hans Gelderblom,  Judith Wessels,  Ferry A L M Eskens,  Natasja de Bont,  Johan W R Nortier,  Henk-Jan Guchelaar
Affiliations

Affiliation

  • 1 Department of Clinical Oncology, Leiden University Medical Centre, K1-P, P.O Box 9600, 2300 RC, Leiden, The Netherlands.
PMID: 19924384 DOI: 10.1007/s10637-009-9347-0
Abstract

Purpose: Telatinib is an orally active small-molecule tyrosine kinase inhibitor of kinase insert domain receptor (KDR; VEGFR-2) and fms-related tyrosine kinase 4 (FLT4; VEGFR-3). This study aims at the identification of relationships between single nucleotide polymorphisms (SNPs) in genes encoding for transporter proteins and pharmacokinetic parameters in order to clarify the significant interpatient variability in drug exposure. In addition, the potential relationship between target receptor polymorphisms and toxicity of telatinib is explored.

Methods: Blood samples from 33 patients enrolled in a phase I dose-escalation study of telatinib were analyzed. For correlation with dose normalized AUC(0-12), ATP-binding cassette (ABC) B1 (ABCB1), ABCC1, and ABCG2 were the genes selected. For correlation with telatinib toxicity, selected genes were the drug target genes VEGFR2/KDR/Flk-1 and FLT4.

Results: No association between dose normalized AUC(0-12) and drug transporter protein polymorphisms was observed. In addition, no association between toxicity and VEGFR2/KDR/Flk-1 or FLT4 genotype or haplotype was seen.

Conclusions: Our pharmacogenetic analysis could not reveal a correlation between relevant gene polymorphisms and clinical and pharmacokinetic observations of telatinib.

Figures
Products